Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

European expert consensus statement on therapeutic goals in Fabry disease

Open access
Wanner, Christoph, Arad, Michael, Baron, Ralf, Burlina, Alessandro, Elliott, Perry M., Feldt-Rasmussen, Ulla, Fomin, Victor V., Germain, Dominique P., Hughes, Derralynn A., Jovanovic, Ana, Kantola, Ilkka, Linhart, Aleš, Mignani, Renzo, Monserrat, Lorenzo, Namdar, Mehdi, Nowak, Albina, Oliveira, João-Paulo, Ortiz, Alberto, Pieroni, Maurizio, Spada, Marco, Tylki-Szymańska, Anna, Tøndel, Camilla, Viana-Baptista, Miguel, Weidemann, Frank, Hilz, Max J. · 2018 · Molecular Genetics and Metabolism

Abstract

BACKGROUND Fabry disease, an inherited lysosomal storage disorder, causes multi-organ pathology resulting in substantial morbidity and a reduced life expectancy. Although Fabry disease is an X-linked disorder, both genders may be affected, but generally to a lesser extent in females. The disease spectrum ranges from classic early-onset disease to non-classic later-onset phenotypes, with complications occurring in multiple organs or being confined to a single organ system depending on the stage of the disease. The impact of therapy depends upon patient- and disease-specific factors and timing of initiation. METHODS A European panel of experts collaborated to develop a set of organ-specific therapeutic goals for Fabry disease, based on evidence identified in a recent systematic literature review and consensus opinion. RESULTS A series of organ-specific treatment goals were developed. For each organ system, optimal treatment strategies accounted for inter-patient differences in disease severity, natural history, and treatment responses as well as the negative burden of therapy and the importance of multidisciplinary care. The consensus therapeutic goals and proposed patient management algorithm take into account the need for early disease-specific therapy to delay or slow the progression of disease as well as non-specific adjunctive therapies that prevent or treat the effects of organ damage on quality of life and long-term prognosis. CONCLUSIONS These consensus recommendations help advance Fabry disease management by considering the balance between anticipated clinical benefits and potential therapy-related challenges in order to facilitate individualized treatment, optimize patient care and improve quality of life.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymgme.2018.06.004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 208

Metadata

Authors
Wanner, C., Arad, M., Baron, R., Burlina, A., Elliott, P. M., Feldt-Rasmussen, U., Fomin, V. V., Germain, D. P., Hughes, D. A., Jovanovic, A., Kantola, I., Linhart, A., Mignani, R., Monserrat, L., Namdar, M., Nowak, A., Oliveira, J.-P., Ortiz, A., Pieroni, M., Spada, M., Tylki-Szymańska, A., Tøndel, C., Viana-Baptista, M., Weidemann, F., & Hilz, M. J.
Venue
Molecular Genetics and Metabolism
Publisher
Elsevier BV
Published
2018-07
Volume
124
Issue
3
Pages
189-203
ISSN
1096-7192 (ISSN-L)
OpenAlex
W2808184073
Cited by
208
References
8
FWCI
11.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European expert consensus statement on therapeutic goals in Fabry disease. https://app.cochat.ai/papers/10.1016/j.ymgme.2018.06.004
The paper
Wanner, C., Arad, M., Baron, R., Burlina, A., Elliott, P. M., Feldt-Rasmussen, U., Fomin, V. V., Germain, D. P., Hughes, D. A., Jovanovic, A., Kantola, I., Linhart, A., Mignani, R., Monserrat, L., Namdar, M., Nowak, A., Oliveira, J.-P., Ortiz, A., Pieroni, M., . . . Hilz, M. J. (2018). European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2018.06.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.